Chong Kun Dang Expands 'Modcol' Cold Medicine Lineup with Acetaminophen and Ibuprofen Options
Chong Kun Dang is expanding its flagship over-the-counter cold medicine lineup by introducing dual active-ingredient options tailored to specific...
Search results for "Chong Kun Dang"
Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2
South Korea’s five major legacy pharmaceutical companies largely extended their revenue growth in the second quarter, but their bottom lines diverged...
Sales Rise 11%, but Chong Kun Dang’s Q2 Operating Profit Slips 10%
Chong Kun Dang posted higher sales in the second quarter of this year, but its operating profit fell 10% from a year...
Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy
CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical...
Global Asset Managers Expand Holdings in South Korean Pharma and Biotech
Major institutional asset managers are steadily increasing their equity stakes in South Korean pharmaceutical and...
117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years
A review of 25 major South Korean pharmaceutical and biotechnology companies revealed 117 recognized industrial...
Fueling the Future of Biohealth: InterBiz Forum Opens in Jeju With a Record 1,500 Tech Deals
The 24th InterBiz Bio Partnering & Investment Forum 2026, a premier biohealth technology deal-making event, opened...
K-Pharma Sets Sights on Veterinary Market: Daewoong Pharmaceutical Leads the Charge
More than 10 South Korean pharmaceutical companies are pivoting toward veterinary medicine as a strategic growth engine.
Korea’s 40th New Drug ‘Nuviju’ Launches: A Three-Way Battle for the Double-Chin Market
Medytox is set to shake up the aesthetic medicine industry with the launch of "Nuviju," a new treatment for submental...
Hanmi Pharmaceutical, CEO Park Jae-hyun Steps Down: Hwang Sang-yeon Appointed as New CEO Candidate
Hanmi Science is replacing CEO Park Jae-hyun of its subsidiary Hanmi Pharmaceutical and forming a new board of...